Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 7:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 33,093 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PLACEBO Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding

NCT00293059
View directory record Official record
Conditions
Metrorrhagia
Interventions
Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
37
States / cities
Lake Havasu City, Arizona • Greenbrae, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2013 · Synced Oct 23, 2026, 7:28 PM EDT
Completed Not applicable Interventional Results available

Light Therapy as Treatment for Fatigue in Multiple Sclerosis

NCT03060759
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Light Therapy box
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 23, 2026, 7:28 PM EDT
Completed Phase 3 Interventional

A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia

NCT05610280
View directory record Official record
Conditions
Hypertriglyceridemia, Cardiovascular Diseases, Atherosclerosis
Interventions
Olezarsen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
68
States / cities
Birmingham, Alabama • Huntsville, Alabama • Beverly Hills, California + 54 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 23, 2026, 7:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Gum Acacia and Blood Glucose

NCT03716479
View directory record Official record
Conditions
Diet Modification
Interventions
Low Fiber, High Fiber, Placebo/Control
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 23, 2026, 7:28 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia

NCT01003379
View directory record Official record
Conditions
Cognitive Dysfunction, Schizophrenia
Interventions
TC-5619, Placebo
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
7
States / cities
National City, California • Torrance, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2013 · Synced Oct 23, 2026, 7:28 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

NCT00250679
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema
Interventions
Arformoterol tartrate inhalation solution, Arformoterol 25 ųg BID, Formoterol 12 ųg BID, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
35 Years and older
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
60
States / cities
Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 23, 2026, 7:28 PM EDT
Terminated Phase 2 Interventional Results available

A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19

NCT04605588
View directory record Official record
Conditions
SARS-CoV Infection, Covid19
Interventions
Nitazoxanide, Placebo Nitazoxanide, Ribavirin, Placebo Ribavirin, Hydroxychloroquine, Placebo Hydroxychloroquine
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
21 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 23, 2026, 7:28 PM EDT
Withdrawn Phase 4 Interventional

Exparel vs Exparel Plus ACB in TKAs

NCT02365727
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Liposomal bupivacaine, Ropivacaine, Epinephrine, Clonidine, Saline
Drug
Lead sponsor
The Hawkins Foundation
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 23, 2026, 7:28 PM EDT
Completed Phase 2 Interventional Results available

Hemodialysis.-Induced Hypotension Therapy for End Stage Kidney Disease

NCT05297786
View directory record Official record
Conditions
Hemodialysis Complication, Hypotension of Hemodialysis
Interventions
Lanadelumab Injection [Takhzyro], Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 23, 2026, 7:28 PM EDT
Completed Phase 2 Interventional Results available

IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3

NCT03401073
View directory record Official record
Conditions
Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy
Interventions
Intravenous immunoglobulin, 0.9% Sodium Chloride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 23, 2026, 7:28 PM EDT
Completed Phase 2 Interventional Results available

Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis

NCT04008069
View directory record Official record
Conditions
Sarcoidosis
Interventions
Sarilumab, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 23, 2026, 7:28 PM EDT
Completed Phase 2 Interventional

Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol

NCT00701883
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Placebo, MBX-8025, Atorvastatin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Huntington Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2015 · Synced Oct 23, 2026, 7:28 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Pulsed Dye Laser and Affirm Laser in the Treatment of Abdominoplasty Scars

NCT00735254
View directory record Official record
Conditions
Abdominoplasty Scars
Interventions
pulsed dye laser, Affirm Laser, combined PDL and Affirm Lasers, Placebo
Device · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Oct 23, 2026, 7:28 PM EDT
Active, not recruiting Phase 3 Interventional

Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

NCT03281954
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Placebo, Atezolizumab
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
1,550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
212
States / cities
Mobile, Alabama • Anchorage, Alaska • Jonesboro, Arkansas + 164 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 23, 2026, 7:28 PM EDT
Completed No phase listed Observational

Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo

NCT02192554
View directory record Official record
Conditions
Agitation Associated With Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
Interventions
Not listed
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
28
States / cities
Tuscaloosa, Alabama • Costa Mesa, California • Lakewood, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Oct 23, 2026, 7:28 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects

NCT00498654
View directory record Official record
Conditions
Typhoid Fever
Interventions
Ty800 (Salmonella typhi) Oral Vaccine
Biological
Lead sponsor
Avant Immunotherapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
5
States / cities
San Diego, California • Melbourne, Florida • Peoria, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2008 · Synced Oct 23, 2026, 7:28 PM EDT
Not listed Phase 4 Interventional

Effects of Ramelteon (8mg) Alone and in Combination With Multi-Component Behavioral Therapy on Sleep and Circadian Phase in Patients With Chronic Insomnia

NCT01180855
View directory record Official record
Conditions
Insomnia
Interventions
Placebo, Rozerem 8mg, Rozerem 8mg in combination with Multi Component Behavior Therapy
Drug · Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 12, 2010 · Synced Oct 23, 2026, 7:28 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy

NCT05612178
View directory record Official record
Conditions
HIV-1
Interventions
3BNC117-LS, 10-1074-LS, Sterile Saline
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Bethesda, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 7:28 PM EDT
Withdrawn Not applicable Interventional

Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study

NCT02795143
View directory record Official record
Conditions
Toxic Epidermal Necrolysis
Interventions
Isotretinoin, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 69 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 23, 2026, 7:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects

NCT01325415
View directory record Official record
Conditions
Amount of NKTR-118 in Blood, Variation in the Heart's Electrical Cycle
Interventions
NKTR-118, moxifloxacin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 23, 2026, 7:28 PM EDT
Not listed Phase 2 Interventional

Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO)

NCT02908035
View directory record Official record
Conditions
Chronic Limb Ischemia
Interventions
Temsirolimus, Saline
Drug
Lead sponsor
Mercator MedSystems, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
8
States / cities
Little Rock, Arkansas • Orange, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 23, 2026, 7:28 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety Study of Miconazole Oil Versus Vehicle on Fungal Infection of the Ear Canal (Otomycosis)

NCT04432376
View directory record Official record
Conditions
Otomycosis
Interventions
miconazole 2% oil, vehicle oil
Drug
Lead sponsor
Hill Dermaceuticals, Inc.
Industry
Eligibility
7 Years and older
Enrollment
382 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
12
States / cities
Chula Vista, California • La Jolla, California • Roseville, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Oct 23, 2026, 7:28 PM EDT
Active, not recruiting Not applicable Interventional

Dry Needling and Shoulder Muscle Blood Flow, Motions, and Pain Sensitivity in Individuals with Shoulder Pain

NCT05596240
View directory record Official record
Conditions
Dry Needling, Shoulder Pain
Interventions
Dry Needling, Sham Dry Needling
Other
Lead sponsor
Texas Woman's University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 23, 2026, 7:28 PM EDT
Completed Not applicable Interventional Results available

Effect of Vitamin D Supplementation on Inflammation and Cardiometabolic Risk Factors in Obese Adolescents

NCT01217840
View directory record Official record
Conditions
Obesity
Interventions
Drisdol (Ergocalciferol) Vitamin D2, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
11 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 23, 2026, 7:28 PM EDT